We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed ...

Bullish option flow detected in Viking Therapeutics (VKTX) with 61,052 calls trading, 8x expected, and implied vol increasing over 32 points to ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss.